Rapport Therapeutics (NASDAQ:RAPP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Rapport Therapeutics (NASDAQ:RAPP) from a sell rating to a hold rating in a research report report published on Sunday morning.

Several other research analysts have also recently commented on RAPP. Wells Fargo & Company set a $51.00 price target on Rapport Therapeutics in a research report on Friday, December 19th. HC Wainwright upped their target price on Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. The Goldman Sachs Group restated a “buy” rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. Citizens Jmp raised their price objective on Rapport Therapeutics from $77.00 to $80.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Finally, BTIG Research restated a “buy” rating and issued a $47.00 target price on shares of Rapport Therapeutics in a research report on Monday, December 8th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $48.33.

Rapport Therapeutics Stock Performance

Shares of NASDAQ:RAPP opened at $27.38 on Friday. Rapport Therapeutics has a 52 week low of $6.43 and a 52 week high of $42.27. The company’s fifty day moving average is $28.66 and its 200-day moving average is $24.01. The company has a market capitalization of $1.30 billion, a PE ratio of -10.10 and a beta of 1.63.

Rapport Therapeutics (NASDAQ:RAPP) last released its earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.06. On average, analysts forecast that Rapport Therapeutics will post -3.65 EPS for the current year.

Insider Activity at Rapport Therapeutics

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $29.64, for a total transaction of $172,890.12. Following the transaction, the chief executive officer directly owned 567,913 shares of the company’s stock, valued at $16,832,941.32. The trade was a 1.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction on Monday, December 15th. The stock was sold at an average price of $30.02, for a total value of $255,170.00. Following the sale, the insider owned 392,642 shares in the company, valued at $11,787,112.84. This trade represents a 2.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 67,655 shares of company stock worth $1,863,705. 13.57% of the stock is owned by insiders.

Institutional Trading of Rapport Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Strs Ohio increased its holdings in Rapport Therapeutics by 23.5% during the 3rd quarter. Strs Ohio now owns 2,100 shares of the company’s stock valued at $62,000 after purchasing an additional 400 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Rapport Therapeutics by 64.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock valued at $70,000 after acquiring an additional 905 shares in the last quarter. Creative Planning raised its stake in shares of Rapport Therapeutics by 12.8% in the third quarter. Creative Planning now owns 11,959 shares of the company’s stock worth $355,000 after purchasing an additional 1,357 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in Rapport Therapeutics in the 3rd quarter worth about $43,000. Finally, Two Sigma Investments LP lifted its position in Rapport Therapeutics by 8.9% during the third quarter. Two Sigma Investments LP now owns 21,500 shares of the company’s stock valued at $639,000 after purchasing an additional 1,757 shares during the period.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.